PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Both yoy net incomes decline, with CRVO at -285.17%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
24.17%
Some D&A expansion while CRVO is negative at -0.69%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Well above CRVO's 100.00% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-9.33%
Negative yoy SBC while CRVO is 21.78%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-80.33%
Both reduce yoy usage, with CRVO at -93.60%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
Both negative yoy AP, with CRVO at -41.03%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-249.09%
Both reduce yoy usage, with CRVO at -3637.19%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-101.42%
Negative yoy while CRVO is 100.04%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-72.30%
Both yoy CFO lines are negative, with CRVO at -44.12%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-455.28%
Negative yoy CapEx while CRVO is 100.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while CRVO is negative at -100.00%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-427.62%
Both yoy lines negative, with CRVO at -100.00%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
Issuance growth of 53916.27% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.